NCT04209595: PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

NCT04209595
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Chemotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Ph+ase 1
Exclusions: Patients with untreated symptomatic brain metastasis- see trial for details
https://ClinicalTrials.gov/show/NCT04209595

Comments are closed.

Up ↑